Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
First received: October 19, 2010
Last updated: January 10, 2011
Last verified: October 2010

Breast cancer can metastasize to the bones, which leads to another treatment if bone metastases are detected. The purpose of the study is to determine, if fluoride PET/CT is superior to bone scintigraphy with technetium. On the other side, the investigators would like to see if FDG-PET/CT is a reliable alternative to dedicated bone imaging to detect bone metastases in patients with breast cancer.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnosis of Sceletal Metastases in c. Mammae: 18F-NaF-PET/Lowdose-CT Versus 99mTc HDP Bone Scintigraphy

Resource links provided by NLM:

Further study details as provided by Rigshospitalet, Denmark:

Estimated Enrollment: 110
Study Start Date: October 2010
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

breast cancer patients who are treated at Rigshospitalet, DK


Inclusion Criteria:

  • histologically proven c. mammae
  • clinically suspicion of bone metastases

Exclusion Criteria:

  • age under 18 years
  • diabetes mellitus
  • pregnancy
  • other known malignant disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01224873

Contact: Christine Winkler, Dr. christine.winkler@rh.regionh.dk

Dep. of Nuclear Medicine & PET, Rigshospitalet Recruiting
Copenhagen, Denmark, 2100
Principal Investigator: Christine Winkler, Dr.         
Sponsors and Collaborators
Rigshospitalet, Denmark
Principal Investigator: Christine Winkler, Dr. Dep. of Nuclear Medicine & PET, Rigshospitalet, Denmark
  More Information

No publications provided

Responsible Party: Dr. Christine Winkler, Department of Nuclear Medicine & PET
ClinicalTrials.gov Identifier: NCT01224873     History of Changes
Other Study ID Numbers: H-3-2010-019
Study First Received: October 19, 2010
Last Updated: January 10, 2011
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by Rigshospitalet, Denmark:
breast cancer
bone metastasis
comparison of diagnostic methods
bone scintigraphy
fluoride PET/CT

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on April 14, 2014